Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$8.40 USD

8.40
310,518

-0.27 (-3.11%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AngioDynamics' (ANGO) fiscal fourth quarter's top line is likely to have been driven by strong demand for its products.

Zacks Equity Research

AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AngioDynamics (ANGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Cintas (CTAS) to Post Q4 Earnings: Will Cost Woes Mar Results?

by Zacks Equity Research

Cintas' (CTAS) Q4 performance is likely to have been hurt by rising costs. However, higher volumes and prices within the Uniform Rental and Facility Services unit are likely to have aided the same.

Zacks Equity Research

Simulations Plus (SLP) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Simulations Plus' (SLP) third-quarter performance is likely to have gained from the healthy adoption of its solutions across various verticals amid continued macroeconomic weakness.

Zacks Equity Research

Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?

by Zacks Equity Research

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

Zacks Equity Research

Merit Medical (MMSI) Expands Suite via Buyouts, Revises FY23 View

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its portfolio is expected to significantly enhance patient outcomes.

Zacks Equity Research

New Strong Sell Stocks for May 18th

by Zacks Equity Research

ANGO, FPAY and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2023.

Zacks Equity Research

Zacks.com featured highlights include Dutch Bros, Chegg, Impinj and AngioDynamics

by Zacks Equity Research

Dutch Bros, Chegg, Impinj and AngioDynamics are part of the Zacks Screen of the Week article.

Zacks Equity Research

Is the Options Market Predicting a Spike in AngioDynamics (ANGO) Stock?

by Zacks Equity Research

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

Lavina Shahu headshot

Sell These 4 Toxic Stocks to Prevent Portfolio Losses

by Lavina Shahu

The basic understanding of toxic stocks can help investors avoid huge losses and derive maximum benefit from their portfolios. Some toxic stocks that investors may consider dumping are BROS, CHGG, PI and ANGO.

Zacks Equity Research

Zacks.com featured highlights include AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva

by Zacks Equity Research

AngioDynamics, Definitive Healthcare, Casella Waste Systems and Enviva are part of the Zacks Screen of the Week article.

Lavina Shahu headshot

4 Toxic Stocks That Are Detrimental to Your Portfolio's Health

by Lavina Shahu

Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.

Zacks Equity Research

Implied Volatility Surging for AngioDynamics (ANGO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

Zacks Equity Research

AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.

Zacks Equity Research

AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 20% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?

by Zacks Equity Research

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

Zacks Equity Research

AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.

Zacks Equity Research

AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

The Cooper Companies (COO) Q4 Earnings Miss Estimates

by Zacks Equity Research

The Cooper Companies (COO) delivered earnings and revenue surprises of -11% and 1.03%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) Up 24.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Rimmi Singhi headshot

4 Toxic Stocks That May Stress You Out Amid Market Turmoil

by Rimmi Singhi

Just like identifying promising stocks, detecting toxic stocks and dumping them at the right time are crucial to safeguarding one's portfolio from big losses.

Zacks Equity Research

AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.

Zacks Equity Research

AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 1.99%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?